as 07-26-2024 4:00pm EST
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.
Founded: | 2014 | Country: | Hong Kong |
Employees: | N/A | City: | N/A |
Market Cap: | 65.1M | IPO Year: | 2021 |
Target Price: | N/A | AVG Volume (30 days): | 263.9K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.45 | EPS Growth: | N/A |
52 Week Low/High: | $3.03 - $32.44 | Next Earning Date: | 06-20-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
RGC Breaking Stock News: Dive into RGC Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
PR Newswire
6 months ago
Business Wire
6 months ago
GlobeNewswire
6 months ago
Thomson Reuters StreetEvents
6 months ago
Zacks
6 months ago
GlobeNewswire
6 months ago
ACCESSWIRE
6 months ago
The information presented on this page, "RGC Regencell Bioscience Holdings Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.